Naeem Goussous

Emergency use of prethawed Group A plasma in trauma patients.

BACKGROUND Massive transfusion protocols lead to increased use of the rare universal plasma donor, Type AB, potentially limiting supply. Owing to safety data, with a goal of avoiding shortages, our blood bank exploited Group A rather than AB for all emergency release plasma transfusions. We hypothesized that ABO-incompatible plasma transfusions had mortality similar to ABO-compatible transfusions. METHODS Review of all trauma patients receiving emergency release plasma (Group A) from 2008 to 2011 was performed. ABO compatibility was determined post hoc. Deaths before blood typing were eliminated. p < 0.05 was considered statistically significant. RESULTS Of the 254 patients, 35 (14%) received ABO-incompatible and 219 (86%) received ABO-compatible transfusions. There was no difference in age (56 years vs. 59 years), sex (63% vs. 63% male), Injury Severity Score (ISS) (25 vs. 22), or time spent in the trauma bay (24 vs. 26.5 minutes). Median blood product units transfused were similar: emergency release plasma (2 vs. 2), total plasma at 24 hours (6 vs. 4), total red blood cells at 24 hours (5 vs. 4), plasma–red blood cells at 24 hours (1.3:1 vs. 1.1:1), and plasma deficits at 24 hours (2 vs. 1). Overall complications were similar (43% vs. 35%) as were rates of possible transfusion-related acute lung injury (2.9% vs. 1.8%), acute lung injury (3.7% vs. 2.5%), adult respiratory distress syndrome (2.9% vs. 1.8%), deep venous thrombosis (2.9% vs. 4.1%), pulmonary embolism (5.8% vs. 7.3%), and death (20% vs. 22%). Ventilator (6 vs. 3), intensive care unit (4 vs. 3), and hospital days (9 vs. 7) were similar. There were no hemolytic reactions. Mortality was significantly greater for the patients who received incompatible plasma if concurrent with a massive transfusion (8% vs. 40%, p = 0.044). Group AB plasma use was decreased by 96.6%. CONCLUSION Use of Group A for emergency release plasma resulted in ABO-incompatible transfusions; however, this had little effect on clinical outcomes. Blood banks reticent to adopt massive transfusion protocols owing to supply concerns may safely use plasma Group A, expanding the pool of emergency release plasma donors. LEVEL OF EVIDENCE Therapeutic study, level IV; prognostic study, level III.

Primary fascial closure after damage control laparotomy: Sepsis vs haemorrhage

OBJECTIVE To compare the outcomes of patients undergoing damage control laparotomy (DCL) for intra-abdominal sepsis vs intra abdominal haemorrhage. We hypothesize that patients undergoing DCL for sepsis will have a higher rate of septic complications and a lower rate of primary fascial closure. SETTINGS AND PATIENTS Retrospective study of patients undergoing DCL from December 2006 to November 2009. Data are presented as medians and percentages where appropriate. RESULTS 111 patients were identified (55 men), 79 with sepsis and 32 with haemorrhage. There was no difference in age (63 vs 62 years), body mass index (BMI, 27 vs 28), diabetes mellitus (13% vs 9%), or duration of initial operation (125 vs 117 min). Patients with sepsis presented with a lower serum lactate (2.2 vs 4.7 mmol/L, p<0.01), base deficit (4.0 vs 8.0, p ≤ 0.01) and ASA score (3.0 vs 4.0, p<0.01). There was no statistical difference in overall morbidity (81% vs 66), mortality (19% vs 22%), intra-abdominal abscess (18% vs 16%), deep wound infection (9% vs 9%), enterocutaneous fistula (ECF) (8% vs 6%) and primary fascial closure (58% vs 59%). Multivariable analysis demonstrated that intra-abdominal abscess (OR 4.26, 95% CI 1.06-19.32), higher base deficit (OR 1.14, 95% CI 1.00-1.31) and more abdominal explorations (OR 1.54, 95% CI 1.23-2.07) were associated with lack of primary fascial closure, but BMI (OR 1.00, 95% CI 0.94-1.07), ECF (OR 2.02, 95% CI 0.23-19.98), wound infection (OR 0.93, 95% CI 0.15-5.27), amount of crystalloids infused within the first 24h (OR 1.00, 95% CI 0.99-1.00) and intra-abdominal sepsis (OR 1.14, 95% CI 0.35-3.80) were not. CONCLUSIONS There was an equivalent rate of septic complications and primary fascial closure rates regardless of cause for DCL. Intra-abdominal abscess, worse base deficit and higher number of abdominal explorations were independently associated with the lack of primary fascial closure.

Long-term outcomes of gastrografin in small bowel obstruction

BACKGROUND The gastrografin (GG) challenge is a diagnostic and therapeutic tool used to treat patients with small bowel obstruction (SBO); however, long-term data on SBO recurrence after the GG challenge remain limited. We hypothesized that patients treated with GG would have the same long-term recurrence as those treated before the implementation of the GG challenge protocol. METHODS Patients ≥18 years who were treated for SBO between July 2009 and December 2012 were identified. We excluded patients with contraindications to the GG challenge (i.e., signs of strangulation), patients having SBO within 6-wk of previous abdominal or pelvic surgery and patients with malignant SBO. All patients had been followed a minimum of 1 y or until death. Kaplan-Meier method and Cox regression models were used to describe the time-dependent outcomes. RESULTS A total of 202 patients were identified of whom 114 (56%) received the challenge. Mean patients age was 66 y (range, 19-99 y) with 110 being female (54%). A total of 184 patients (91%) were followed minimum of 1 year or death (18 patients lost to follow-up). Median follow-up of living patients was 3 y (range, 1-5 y). During follow-up, 50 patients (25%) experienced SBO recurrences, and 24 (12%) had exploration for SBO recurrence. The 3-year cumulative rate of SBO recurrence in patients who received the GG was 30% (95% confidence interval [CI], 21%-42%) compared to 27% (95% CI, 18%-38%) for those who did not (P = 0.4). The 3-year cumulative rate of exploration for SBO recurrence in patients who received the GG was 15% (95% CI, 8%-26%) compared to 12 % (95% CI, 6%-22%) for those who did not (P = 0.6). CONCLUSIONS The GG challenge is a clinically useful tool in treating SBO patients with comparable long-term recurrence rates compared to traditional management of SBO.

Su1766 HIDA Scan for Gallbladder Dysfunction: Ensure That You Know How the Scan Was Done

(converted to proportions) of mortality was 1.7% (±2.4%) and mean probability of morbidity was 23.5% (±10.9%). There were no significant differences in mean probability of mortality for patients with fibrosis, cirrhosis, steatosis and steatohepatitis (all p>0.05). Hemi-hepatectomy or extended resections were associated with higher probability of mortality, compared to resection of <3 segments (p<0.001). Ascites and thrombocytopenia were associated with higher probability ofmortality (both p≤0.038). Extent of resection and fibrosis were associated higher probability of morbidity (both p<0.001). Underlying liver cirrhosis was not associated with post-operative morbidity (p=0.059). Conclusions: In patients selected for hepatic resection, majority of clinical metrics of chronic liver disease were not associated with differences in ACS NSQIP estimated probability of mortality. However, ascites and thrombocytopenia were associated with significant differences in ACS NSQIP risk stratification model estimated risks of post-operative mortality. Estimates of post-operative mortality and morbidity after hepatic resection can be potentially improved by including selected metrics of underlying chronic liver disease.